GlassScriptPhysician profile
Colleen Rundle
NPI 1598310757
$2,339.90
in general payments reported to CMS, 2019-2025
25 companies · $1,466 in 2025
The $1,466 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $123 · 2022: $18.04 · 2023: $116 · 2024: $618 · 2025: $1,466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,199.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $451.31 | 2023-2025 | Wegovy, Ozempic |
| Abbvie INC. | $328.16 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $186.50 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $182.34 | 2023-2025 | Zepbound, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $136.73 | 2025 | |
| Xeris Pharmaceuticals, INC. | $127.70 | 2024-2025 | Keveyis, Gvoke Hypopen, Recorlev |
| Astellas Pharma US INC | $123.17 | 2025 | Veozah |
| Medical Device Business Services, INC. | $122.62 | 2021 | |
| Exact Sciences Corporation | $113.09 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Pfizer INC. | $111.13 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $66.44 | 2024-2025 | Spravato |
| Antares Pharma, INC. | $58.53 | 2024-2025 | Xyosted |
| Lundbeck LLC | $52.03 | 2025 | Rexulti |
| Amgen INC. | $37.87 | 2024-2025 | Krystexxa |
| Dexcom, INC. | $32.11 | 2024-2025 | Dexcom G6 Transmitter |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $30.44 | 2025 | Capvaxive, Gardasil 9 |
| Sanofi Pasteur INC. | $23.11 | 2025 | |
| Corcept Therapeutics | $22.31 | 2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.22 | 2024 | Ofev |
| Mylan Specialty L.P. | $21.51 | 2023 | Yupelri |
| Intuitive Surgical, INC. | $20.58 | 2023 | Da Vinci Surgical System |
| Vivus LLC | $19.27 | 2024 | Qsymia |
| Ethicon US, LLC | $18.04 | 2022 | |
| Glaxosmithkline, LLC. | $16.98 | 2025 | Shingrix, Arexvy, Bexsero |
| E.R. Squibb & Sons, L.L.C. | $15.71 | 2025 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colleen Rundle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.